Revolution Medicines (RVMD) reported a Q3 net loss late Wednesday of $0.94 per diluted share, compared with a loss of $0.99 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.90.
The company did not report any revenue for the quarter ended Sept. 30. Analysts surveyed by Capital IQ expected $350,000.
Revolution reiterated the projected full-year 2024 net loss guidance of between $560 million and $600 million.
The company projected that its current cash, cash equivalents and marketable securities can fund planned operations into 2027.
Price: 58.00, Change: -1.42, Percent Change: -2.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments